Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(22 intermediate revisions by the same user not shown)
Line 6: Line 6:
 
</div>
 
</div>
  
−
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. It is designed for easy use and intended for healthcare professionals. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please '''[[Tutorial|go to the tutorial page]]''' or just start exploring!</big></div>
+
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div>
  
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
|-
 
|-
−
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 4,587
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,087
−
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimen_variants|<span style="color:black;">Regimen variants</span>]]: {{#ask: [[Variant::+]] |?Variant|limit=10000|format=sum}}
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:#3c0008;">Guidelines: 1,217</span>
−
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,407
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,665
−
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,298
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,589
 
|-
 
|-
 
|}
 
|}
Line 92: Line 92:
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]]
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]]
 
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
−
|style="background-color:#deebf7"|
+
|style="width: 25%; background-color:#deebf7"|[[Small bowel adenocarcinoma]]
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal'''
Line 102: Line 102:
 
|-
 
|-
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]]  
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]]  
−
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreateic adenocarcinoma, BRCA-mutated]]
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreatic adenocarcinoma, BRCA-mutated]]
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]]
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
Line 108: Line 108:
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Bladder cancer]]
 
 
|style="background-color:#deebf7"|[[Penile cancer]]
 
|style="background-color:#deebf7"|[[Penile cancer]]
 
|style="background-color:#deebf7"|[[Prostate cancer]]
 
|style="background-color:#deebf7"|[[Prostate cancer]]
 
|style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]]
 
|style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]]
 +
|style="background-color:#deebf7"|[[Testicular cancer]]
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
 
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
Line 120: Line 120:
 
|style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
 
|style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
 
|style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
 
|style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
−
|style="background-color:#deebf7"|[[Testicular cancer]]
+
|style="background-color:#deebf7"|
 +
|style="background-color:#deebf7"|
 +
|-
 +
|style="background-color:#deebf7"|[[Urothelial carcinoma]]
 +
|style="background-color:#deebf7"|[[Bladder cancer]]
 
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
 
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
 +
|style="background-color:#deebf7"|
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
Line 144: Line 149:
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
+
|colspan="2" style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
−
|style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
+
|colspan="2" style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
−
|style="background-color:#deebf7"|
 
−
|style="background-color:#deebf7"|
 
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
Line 331: Line 334:
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocyte disorders'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
 
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
Line 392: Line 395:
 
|-
 
|-
 
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
 
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
−
|style="background-color:#efedf5"|
+
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
 
|style="background-color:#efedf5"|
 
|style="background-color:#efedf5"|
 
|style="background-color:#efedf5"|
 
|style="background-color:#efedf5"|
Line 405: Line 408:
 
|-
 
|-
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
 +
|-
 
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
−
|-
 
 
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]]
 
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
 
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
 +
|-
 
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
 
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
 
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
 
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
 +
|style="background-color:#e5f5e0"|
 +
|style="background-color:#e5f5e0"|
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
 
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
Line 426: Line 434:
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders'''
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
 
|-
 
|-
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
Line 433: Line 441:
 
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
 
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
 
|-
 
|-
−
|style="background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
+
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
−
|style="background-color:#e5f5e0"|
 
−
|style="background-color:#e5f5e0"|
 
−
|style="background-color:#e5f5e0"|
 
−
|-
 
−
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemoglobinopathies'''
 
−
|-
 
 
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
 
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
 
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
 
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
−
|style="background-color:#e5f5e0"|
 
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
Line 455: Line 456:
  
 
Priorities of this project include:
 
Priorities of this project include:
 +
<section begin=goals />
 
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
 
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
 
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
 
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
Line 460: Line 462:
 
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
 
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
 
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
 
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
 +
<section end=goals />
  
 
Additional possibilities for this project may include:
 
Additional possibilities for this project may include:

Revision as of 12:20, 1 June 2024


HemOnc.org - A Free Hematology/Oncology Reference

HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
Regimens: 5,087 Guidelines: 1,217 Studies: 6,665 References: 7,589
Solid Tumors Malignant Hematology Pediatrics Transplant & IEC Classical Hematology

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, ER-positive Breast cancer, HER2-positive Breast cancer, ER and HER2 co-expressing
Breast cancer, triple negative (TNBC) Breast cancer, BRCA-mutated Breast cancer, PIK3CA-mutated
Dermatologic Oncology
Cutaneous BCC Cutaneous SCC Melanoma Melanoma, BRAF-mutated
Melanoma, KIT-mutated Melanoma, NRAS-mutated Merkel cell carcinoma (MCC) Uveal melanoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumor (NET) Neuroendocrine carcinoma (NEC) Pancreatic NET
Pheochromocytoma Thyroid cancer Differentiated thyroid cancer (DTC) Medullary thyroid cancer (MTC)
Thyroid cancer, BRAF-mutated Thyroid cancer, RET-positive
Gastrointestinal Oncology, Intestinal
Anal cancer Appendiceal tumor Colon cancer Colon cancer, RAS wild-type
Colorectal cancer (CRC) CRC, BRAF-mutated CRC, HER2-positive CRC, MSI-H or dMMR
CRC, RAS wild-type Esophageal cancer Esophageal adenocarcinoma Esophageal SCC
Gastric cancer Gastric cancer, HER2-positive Rectal cancer Small bowel adenocarcinoma
Gastrointestinal Oncology, Extraintestinal
Cholangiocarcinoma Gallbladder cancer Hepatocellular carcinoma (HCC) Periampullary adenocarcinoma
Pancreatic adenocarcinoma Pancreatic adenocarcinoma, BRCA-mutated Pancreatic NET
Genitourinary Oncology
Penile cancer Prostate cancer Prostate cancer, BRCA-mutated Testicular cancer
Renal cell carcinoma (RCC) Clear cell RCC (ccRCC) Non-clear cell RCC (nccRCC) Papillary RCC
Sarcomatoid RCC VHL-associated RCC
Urothelial carcinoma Bladder cancer Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Low-grade serous ovarian cancer (LGSOC)
Ovarian cancer Ovarian cancer, BRCA-mutated Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma (NPC) HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM) Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Anaplastic glioma Craniopharyngioma Glioblastoma (GBM) Low-grade glioma
Meningioma Subependymal giant cell astrocytoma (SEGA)
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Sarcoma
Bone sarcoma Ewing sarcoma Giant-cell tumor of bone Osteosarcoma
Soft tissue sarcoma (STS) Alveolar soft part sarcoma (ASPS) Dermatofibrosarcoma protuberans Desmoid tumor
Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Inflammatory myofibroblastic tumor (IMT) Leiomyosarcoma (LMS)
Liposarcoma PEComa Rhabdomyosarcoma (RMS) Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma Angiosarcoma Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) NSCLC, nonsquamous NSCLC, squamous NSCLC, ALK-positive
NSCLC, BRAF-mutated NSCLC, EGFR-mutated NSCLC, HER2-mutated NSCLC, KRAS-mutated
NSCLC, MET-mutated NSCLC, RET-positive NSCLC, ROS1-positive NSCLC, CNS metastases
Small cell lung cancer (SCLC) Thymoma
Site-agnostic
BRAF EGFR ERBB2 (HER2) ERBB3 (HER3)
MSI-H or dMMR NTRK RET SMO or PTCH-1 (Hedgehog)
TMB-H Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated AML, NPM1-mutated
Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS) Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma Classical Hodgkin lymphoma (cHL) CNS lymphoma Diffuse large B-cell lymphoma (DLBCL)
High-grade B-cell lymphoma HIV-associated lymphoma Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL)
Primary mediastinal B-cell lymphoma (PMBL) Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
MALT lymphoma Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia (PCL) POEMS syndrome Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia NK- and T-cell lymphoma (NKTCL) Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD) Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis (LCH) Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma High-grade glioma Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL) Chronic myeloid leukemia (CML) Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL) Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma Ewing sarcoma Hepatoblastoma Neuroblastoma
Osteosarcoma Rhabdomyosarcoma Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization Allogeneic HSCT Autologous HSCT Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD) Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Acquired thrombotic thrombocytopenic purpura (aTTP) Antiphospholipid antibody syndrome (APLAS) Congenital thrombotic thrombocytopenic purpura (cTTP)
Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT) Inherited coagulopathy Inherited thrombophilia
Thrombotic microangiopathy (TMA) Venous thromboembolism (VTE)
Cytopenias
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS) Warm autoimmune hemolytic anemia (WAIHA) Cold agglutinin disease (CAD) Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD) Beta thalassemia Sickle cell anemia
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:

Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.


Retrieved from "https://hemonc.org/w/index.php?title=Main_Page&oldid=86147"